PTC-209

Cas No.:	315704-66-6
Chemical Name:	N-(2,6-dibromo-4-methoxyphenyl)-4-(2-methylimidazo[1,2-a]pyrimidin-3-yl)thiazol-2-amine
Synonyms:	PTC209; PTC 209
SMILES:	S1C=C(C2N3C(=NC=2C)N=CC=C3)N=C1NC1=C(Br)C=C(OC)C=C1Br
Formula:	C17H13Br2N5Os
M.Wt:	495.19
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	PTC-209 is a specific BMI-1 inhibitor with an IC50 of 0.5 μM.
In Vivo:	Pharmacokinetic analysis demonstrates that PTC-209 (60 mg/kg, subcutaneously once a day) effectively inhibits BMI-1 production in tumor tissue in vivo. Inhibition of BMI-1 with PTC-209 halts growth of preestablished tumors in vivo[1].
In Vitro:	PTC-209 is a recently developed inhibitor of BMI1, in biliary tract cancer (BTC) cells. PTC-209 reduces overall viability in BTC cell lines in a dose-dependent fashion (0.04-20 μM). Treatment with PTC-209 leads to slightly enhanced caspase activity and stop of cell proliferation. Cell cycle analysis reveals that PTC-209 causes cell cycle arrest at the G1/S checkpoint[2]. PTC-209 (100, 200, or 500 nM) decreases BMI1 and increases p16 protein expression in canine OSA cell lines. Compare to vehicle control, BMI1 protein expression decreases by 40% and 25% in the Abrams and D17 cell lines, respectively, following 500 nM PTC-209 treatment. In the Moresco cell line, BMI1 protein expression decreases by 16% and 39% following 200 nM and 500 nM PTC-209 treatment, respectively, as compared to vehicle control. Increases in p16 protein levels can be observed in all cell lines beginning at 100 nM PTC-209 and are highest at the 500 nM PTC-209 dose for Abrams (120% increase) and Moresco (200% increase), but appeares to top out at 200 nM for the D17 cell line (54% increase)[3].